05 December 2016
The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments.
The latest health warning covers some of the top-selling products in the multi-billion dollar hepatitis C market, including Sovaldi, Exviera, Viekirax, Olysio and Daklinza.
These drugs cure well over 90 percent of patients with the liver disease and also cuts down the duration of the treatment.
The Pharmacovigilance Risk Assessment Committee (PRAC), part of the EMA, said it suspected the reactivation of the hepatitis B virus was due to the rapid reduction of the hepatitis C virus, which is known to suppress the hepatitis B virus.
The agency recommended that patients be screened to ensure they are not infected with both the viruses before being treated for hepatitis C.
It also recommended that a warning be included in the label for these medicines.
The U.S. Food and Drug Administration had issued a similar warning in October, with similar recommendations.
The latest warning from the EMA follows one in April when it said that data showed that patients taking hepatitis C drugs were at risk of their liver cancer returning.
However, the PRAC said on Friday that further studies were needed before firm conclusions could be drawn.
Gilead Sciences Inc makes Sovaldi. AbbVie Inc makes Exviera and Viekirax. Johnson & Johnson makes Olysio and Bristol-Myers Squibb makes Daklinza.
The shares of the four drugmakers were up between 0.1 percent and 0.7 percent on Friday afternoon, roughly in line with the broader health index's 0.5 percent increase.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024